Generate Biomedicines
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions increased by 16 in the most recent period (2026/Q3).
- Total institutional ownership rose 4.9 percentage points.
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 83.21% +4.85pp
- Institutions
- 120 +16
- As of
- 2026/Q3 vs. prior period
Holder types
Top holders as of 2026-06-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
43 filings tracked · 19 buys · 3 sells
| Name | Role | Stake |
|---|---|---|
| Flagship Pioneering, Inc | -- | 48.83% |
| Michael Nally | Chief Executive Officer | 2.25% |
| Stéphane Bancel | Independent Director | 0.92% |
| Gevorg Grigoryan | Chief Technology Officer | 0.51% |
| Frances Arnold | Independent Director | 0.35% |
| Noubar Afeyan | Co-founder & Independent Chair of the Board | 0.02% |
| Jane Mendillo | Independent Director | 0.00% |
| Jason Silvers | President | 0.00% |
| Beth Grous | Chief Human Resources Officer | 0.00% |
| Paul Parker | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-28 | Frances Arnold | Independent Director | Automatic Disposition | -11,409 | $16.19 |
| 2026-09-01 | Frances Arnold | Independent Director | Intent to Sell (Form 144) | -32,210 | $16.16 |
| 2026-08-31 | Frances Arnold | Independent Director | Automatic Disposition | -1,000 | $16.00 |
| 2026-03-03 | Michael Nally | Chief Executive Officer | Open Market Acquisition | +20,000 | $12.00 |
| 2026-03-01 | Jane Mendillo | Independent Director | Private Acquisition | +1,500 | $16.00 |
| 2026-03-01 | Stéphane Bancel | Independent Director | Derivative Exercise and Retained | +724,160 | -- |
| 2026-03-01 | Michael Nally | Chief Executive Officer | Derivative Exercise and Retained | +658,327 | -- |
| 2026-03-01 | Beth Grous | Chief Human Resources Officer | Private Acquisition | +300 | $16.00 |
| 2026-03-01 | Jason Silvers | President | Private Acquisition | +2,000 | $16.00 |
| 2026-02-25 | Flagship Pioneering, Inc | -- | Initial Statement of Beneficial | 0 | -- |
| 2026-02-25 | Noubar Afeyan | Co-founder & Independent Chair of the Board | Initial Statement of Beneficial | 0 | -- |
| 2026-02-25 | Paul Parker | Independent Director | Other Derivative Acquisition | +29,561 | $16.00 |
| 2026-02-25 | Paul Parker | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-02-25 | Marsha Fanucci | Independent Director | Other Derivative Acquisition | +29,561 | $16.00 |
| 2026-02-25 | Marsha Fanucci | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-02-25 | Nancy Simonian | Independent Director | Other Derivative Acquisition | +29,561 | $16.00 |
| 2026-02-25 | Nancy Simonian | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-02-25 | Frances Arnold | Independent Director | Other Derivative Acquisition | +29,561 | $16.00 |
| 2026-02-25 | Frances Arnold | Independent Director | Initial Statement of Beneficial | 0 | -- |
| 2026-02-25 | Jane Mendillo | Independent Director | Other Derivative Acquisition | +29,561 | $16.00 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:32:29 · For reference only, not investment advice and not tailored to your situation.
Generate Biomedicines discussion 0 comments